Drug Approval | August 31, 2025
FDA suspends Valneva’s license of chikungunya vaccine IXCHIQ in US
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Singhal brings a powerful blend of operational excellence, investor acumen, and visionary thinking
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Capricor’s BLA for Deramiocel received Priority Review in March 2025
These medicines are essential in preventing RhD immunisation during pregnancy
Star Health Insurance is modernising its claims ecosystem to be future-ready
Subscribe To Our Newsletter & Stay Updated
